Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus with Chemotherapy in Relapsed/Refractory MCL
NCT01389427Phase 2Completed
- Sponsor
- LYSARC
- Start
- Nov 2011
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of temsirolimus in mantle cell lymphoma (MCL) (4 arms), sponsored by LYSARC. Primary endpoint: Incidence of Dose Limiting Toxicities at 56 days. Started Nov 2011; status: completed.
02
Drugs
temsirolimus
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01389427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01389427.